🇺🇸 FDA
Patent

US 9636416

Immunoglobulin chimeric monomer-dimer hybrids

granted A61KA61K38/00A61K47/60

Quick answer

US patent 9636416 (Immunoglobulin chimeric monomer-dimer hybrids) held by BIOVERATIV THERAPEUTICS INC. expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K38/00, A61K47/60, A61K47/642, A61K47/68